Eagle Pharmaceuticals Inc said on Wednesday the U.S. health regulator approved its generic version of Endo International’s blood pressure drug, Vasostrict, sending its shares to a more than one-month high.
The U.S. Food and Drug Administration’s approval comes just months after a Delaware federal court ruled that Eagle’s proposed generic, vasopressin, did not infringe on patents held by Endo subsidiary Par Pharmaceutical.
